PROCEPT BioRobotics Corporation

As of June 30, 2026, PROCEPT BioRobotics Corp. carries a market capitalization of 28.74B, placing it among publicly traded companies globally. Its enterprise value stands at 26.11B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

PROCEPT BioRobotics Corp.'s next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, PROCEPT BioRobotics Corp. has 57.25M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 4.80, and the price-to-book ratio stands at 4.84.

These figures are as of June 30, 2026. The EV/Sales ratio of 4.43 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 26.11B versus a market cap of 28.74B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, PROCEPT BioRobotics Corp. maintains a current ratio of 6.55, meaning it holds 6.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 22.79, indicating elevated leverage, while an interest coverage ratio of -30.86 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, PROCEPT BioRobotics Corp. posted a negative return on equity (ROE) of -30.24, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -22.12, reflecting losses generated across the asset base. The company generates approximately 6.89M in revenue per employee across its workforce of 855.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.68 indicates how many times PROCEPT BioRobotics Corp. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, PROCEPT BioRobotics Corp. recorded 891,051.60 in income tax expense. The company reported a pretax loss of -1.91B and -1.92B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Over the twelve months ended June 30, 2026, PROCEPT BioRobotics Corp. generated 5.89B in revenue and converted that into -1.92B in net income, yielding earnings per share of -34.03. EBITDA reached -1.87B, while operating income came in at -2.00B.

As of June 30, 2026, PROCEPT BioRobotics Corp. holds 3.98B in cash and equivalents against 1.35B in total debt, resulting in a net debt position of -3.08B. Total book value stands at 5.94B, with working capital of 6.22B providing operational flexibility.

PROCEPT BioRobotics Corp. produced -1.30B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -184.94M in capital expenditures, free cash flow totaled -1.48B - equivalent to -26.33 per share.

Over the twelve months ended June 30, 2026, PROCEPT BioRobotics Corp. posted a gross margin of 64.22, reflecting its pricing power and cost economics. The operating margin of -33.86 and net profit margin of -32.54 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -5.25: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.62, meaning PROCEPT BioRobotics Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, PROCEPT BioRobotics Corp. has an Altman Z-Score of 5.85, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.